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background:  It is controversial that proton pump inhibitor (PPI) might affect clopidogrel platelet response and can be associated with 
major adverse cardiovascular events (MACEs) in patients (pts) undergoing percutaneous coronary intervention (PCI). Particularly impact of 
PPI on pts with triple antiplatelets (TAT) following PCI is largely unknown.
methods:  A total 3747 patients (pts) undergoing PCI were investigated. The pts were classified into dual antiplatelet therapy (DAT; 
aspirin+clopidogrel) and TAT (DAT+cilostazol) according to discharge medication. Finally, 2209 pts was enrolled in the DAT group and 697 
pts in the TAT group. Major clinical outcomes at one year were compared between the two groups.
results:  At baseline, age, gender, diabetes, hypertension, dyslipidemia, cerebrovascular accident, and current smoking were balanced 
between PPI user and non-PPI user group in both DAT and TAT. Not only in DAT group but also in TAT group, there was no significant 
differences in clinical outcomes including total death, cardiac death, myocardial infarction, revascularization, all major adverse 
cardiovascular event (MACE), target lesion revascularization (TLR)-MACE, target vessel revascularization (TVR)-MACE, and stent 
thrombosis between PPI user and non-PPI user (Table).
Conclusion:  In our study, chronic PPI use was not associated with adverse cardiovascular outcomes up to 1-year in Korean pts 
undergoing PCI regardless of DAT and TAT.
 
